Clinical Trial

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-12-05; most recent amendment 2025-02-27.
Trial Details
NCT Number NCT05648591
Lead Sponsor Vanda Pharmaceuticals
Conditions Schizophrenia, Bipolar I Disorder
Enrollment 100 participants
Start Date 2023-05-24
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-04